文献速递胸部肿瘤

早期缓解深度对EGFR突变肺癌长期预后的预测价值

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2018-03-23

该研究基于五项随机试验的个体患者数据,分析晚期EGFR突变非小细胞肺癌患者6周和12周肿瘤缓解深度与生存结局的关系。结果显示,尽管EGFR-TKI较化疗有更深的肿瘤缩小和PFS优势,但缓解深度与PFS或OS无显著关联,提示其不宜作为获益的替代指标。

要点

  • EGFR-TKI较化疗的PFS获益不能由缓解深度解释。
  • 缓解深度不应作为未来试验或临床决策的替代终点。

核心结论

  • 在晚期EGFR突变NSCLC中,6周或12周缓解深度不能解释EGFR-TKI相对于化疗的PFS优势,不应作为获益的替代指标。

研究设计与样本

  • 基于EURTAC、IPASS、ENSURE、LUX-Lung 3和LUX-Lung 6五项随机试验的个体患者数据,采用里程碑分析。

主要发现

  • 6周时可评估且无疾病进展的患者共1081例,其中71.2%达到RECIST缓解。

关键数值与推荐

  • 缓解深度基于6周和12周影像评估,计算靶病灶最长径之和相对基线的变化。
  • 6周时71.2%的患者达到RECIST缓解。

临床怎么用

  • 临床决策中不应依据早期肿瘤缩小深度来预测EGFR-TKI的长期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Traditionally, marked tumor shrinkage has been assumed to portend better outcome. We investigated whether depth of tumor response was associated with improved survival outcomes in advanced EGFR-mutant NCLC. METHODS: Individual patient data from randomized trials (EURTAC, IPASS, ENSURE, LUX-Lung 3, and LUX-Lung 6) were used. The association of depth of response with progression-free survival (PFS) and overall survival was examined using landmark analyses. Depth of response based on radiologic assessments at 6 weeks and 12 weeks was calculated as the relative changes in the sum of the longest diameters of the target lesions from baseline. RESULTS: Of 1081 evaluable patients at 6 weeks with no disease progression, 71.2% achieved Response Evaluation Criteria in Solid Tumors response. Using a landmark analysis, EGFR-TKI was more effective than chemotherapy (PFS hazard ratio = 0.36, p < .0001); and was associated with greater mean tumor shrinkage than chemotherapy (35.1% versus 18.5%, p < .0001). However, there was no significant difference in the relative PFS benefit between treatment groups across the entire spectrum of tumor shrinkage (p = .18 for test of interaction between treatment and continuously measured depth of response). Depth of response at 6 weeks was not associated with PFS when adjusted for treatment effect (hazard ratio = 0.96, p = .78). Similar results were obtained for 12-week landmark analysis and for OS outcome. CONCLUSIONS: The PFS advantage of EGFR-TKI over chemotherapy in advanced EGFR mutant NCLC is not explained by depth of response at 6 or 12 weeks. It should not be used as a surrogate of benefit in future trials or routine clinical decision making.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lee CK, Lord S, Marschner I, et al. The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2018. PMID: 29580950. doi:10.1016/j.jtho.2018.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。